Aldometanib (C09-1103-449)

Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis Appearance:SolidIn Vitro:Aldometanib (0-1000 nM; 2 h) activates AMPK by preventing aldolase from binding to FBP to engender a pseudo-starvation signal. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCIn Vivo:Aldometanib (oral; 0-10 mpk) reduces blood glucose in lean mice. Aldometanib (oral; 2-10 mpk; twice daily; for a week) reduces blood glucose and alleviates fatty liver in obese hyperglycaemic mice. Aldometanib alleviates fatty liver and nonalcohBiological Activity:Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis. Specification: 0.99 Molecular Formula: C27H43Cl2IN2 Molecular Weight: 593.45